431 related articles for article (PubMed ID: 34429382)
1. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
Salter AI; Rajan A; Kennedy JJ; Ivey RG; Shelby SA; Leung I; Templeton ML; Muhunthan V; Voillet V; Sommermeyer D; Whiteaker JR; Gottardo R; Veatch SL; Paulovich AG; Riddell SR
Sci Signal; 2021 Aug; 14(697):. PubMed ID: 34429382
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
3. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
4. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
Kitano S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
[TBL] [Abstract][Full Text] [Related]
5. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
6. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
7. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
8. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
9. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.
Wu W; Zhou Q; Masubuchi T; Shi X; Li H; Xu X; Huang M; Meng L; He X; Zhu H; Gao S; Zhang N; Jing R; Sun J; Wang H; Hui E; Wong CC; Xu C
Cell; 2020 Aug; 182(4):855-871.e23. PubMed ID: 32730808
[TBL] [Abstract][Full Text] [Related]
10. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
[TBL] [Abstract][Full Text] [Related]
11. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
13. The signaling and the metabolic differences of various CAR T cell designs.
Razavi AS; Loskog A; Razi S; Rezaei N
Int Immunopharmacol; 2023 Jan; 114():109593. PubMed ID: 36700773
[TBL] [Abstract][Full Text] [Related]
14. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
17. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
18. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
20. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
